Please provide your email address to receive an email when new articles are posted on . Lenalidomide maintenance therapy significantly improved PFS compared with observation among patients with newly ...

Data from a large phase III trial presented at the 2022 American Society of Hematology (ASH) annual meeting examined the relationship between minimal residual disease, progression-free survival, and ...

Phase I data presented at the 2023 American Society of Hematology (ASH) annual meeting showed the benefit of lenalidomide (Revlimid) rechallenge in relapsed/refractory multiple myeloma patients ...

As a precursor to myeloma, smoldering multiple myeloma (MM) currently has no treatment. In fact, the standard of care is observation until the patient starts to present with symptoms. However, ...

The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an ...

The TGA registration establishes Minjuvi as the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for this group of patients. 2 ...

Within a selection of therapies showing efficacy over a placebo, lenalidomide-carfilzomib was a standout against the rest of the group. “Despite advances in novel agents, the relapse and progression ...

Please provide your email address to receive an email when new articles are posted on . Lenalidomide resulted in a prolonged time to subsequent therapy in high-risk CLL. Lenalidomide did not seem to ...

REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous ...

The recommended starting dosage of lenalidomide for the treatment of MM is 25 mg/day p.o. on days 1-21 of a 28-day cycle. On the basis of the trials previously presented, the recommended dosage of ...

The thalidomide analog lenalidomide has more-potent preclinical activity than thalidomide, and is efficacious in patients with relapsed and refractory myeloma when used alone or in combination with ...